Last reviewed · How we verify

Sphenopalatine Ganglion Block

University Hospital, Clermont-Ferrand · FDA-approved active Small molecule

A sphenopalatine ganglion block is a minimally invasive procedure that interrupts pain signals by anesthetizing the sphenopalatine ganglion, a parasympathetic nerve cluster in the pterygopalatine fossa.

A sphenopalatine ganglion block is a minimally invasive procedure that interrupts pain signals by anesthetizing the sphenopalatine ganglion, a parasympathetic nerve cluster in the pterygopalatine fossa. Used for Acute migraine headache, Cluster headache, Trigeminal neuralgia.

At a glance

Generic nameSphenopalatine Ganglion Block
Also known asSGB
SponsorUniversity Hospital, Clermont-Ferrand
ModalitySmall molecule
Therapeutic areaNeurology
PhaseFDA-approved

Mechanism of action

The sphenopalatine ganglion is a key relay station for parasympathetic innervation to the head and face. By delivering local anesthetic directly to this ganglion via transnasal or other approaches, the procedure blocks pain transmission associated with headaches and facial pain conditions. This interruption of autonomic signaling provides rapid pain relief, particularly for acute migraine and cluster headache attacks.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: